$5.325
-0.125[-2.29%]
Last update: 1:01PM Get Real Time Here
Travere Therapeutics
(NASDAQ:TVTX)Travere Therapeutics Stock (NASDAQ:TVTX), Analyst Ratings, Price Targets, Predictions
Travere Therapeutics Inc has a consensus price target of $22.16, established from looking at the 67 latest analyst ratings. The last 3 analyst ratings were released from HC Wainwright & Co., Wedbush, and Guggenheim on April 24, 2024, April 17, 2024, and March 27, 2024. With an average price target of $10.67 between HC Wainwright & Co., Wedbush, and Guggenheim, there's an implied 100.31% upside for Travere Therapeutics Inc from these 3 analyst ratings.
Analyst Firms Making Recommendations1
HC Wainwright & Co.
Wedbush
Guggenheim
Wells Fargo
Piper Sandler
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for Travere Therapeutics
date | ticker | Buy Now | Company | Current price | Upside/Downside | Analyst Firm | Analyst & % Accurate | Price Target Change | Rating Change | Previous / Current Rating | Get Alert |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 04/24/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 256.81% | HC Wainwright & Co. | Ed Arce | $17 → $19 | Maintains | Buy | Get Alert |
| 04/17/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 144.13% | Wedbush | Laura Chico | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 03/27/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | — | Guggenheim | Vamil Divan | — | Downgrade | Buy → Neutral | Get Alert |
| 03/13/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 219.25% | HC Wainwright & Co. | Ed Arce | $17 → $17 | Maintains | Buy | Get Alert |
| 02/16/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 69.01% | Wells Fargo | Mohit Bansal | $8 → $9 | Maintains | Equal-Weight | Get Alert |
| 02/16/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 144.13% | Wedbush | Laura Chico | → $13 | Reiterates | Outperform → Outperform | Get Alert |
| 01/18/2024 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 106.57% | Piper Sandler | Nicole Gabreski | $10 → $11 | Maintains | Neutral | Get Alert |
| 12/18/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 87.79% | Stifel | Alex Thompson | $8 → $10 | Maintains | Hold | Get Alert |
| 12/15/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 275.59% | HC Wainwright & Co. | Ed Arce | $18 → $20 | Maintains | Buy | Get Alert |
| 12/05/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 87.79% | Citigroup | Carly Kenselaar | $7 → $10 | Upgrade | Neutral → Buy | Get Alert |
| 12/05/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 238.03% | HC Wainwright & Co. | Ed Arce | → $18 | Reiterates | Buy → Buy | Get Alert |
| 11/20/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 31.46% | Citigroup | Carly Kenselaar | → $7 | Initiates | → Neutral | Get Alert |
| 10/25/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 87.79% | Piper Sandler | Nicole Gabreski | $19 → $10 | Maintains | Neutral | Get Alert |
| 09/29/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 125.35% | Wedbush | Laura Chico | → $12 | Reiterates | Outperform → Outperform | Get Alert |
| 09/22/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 125.35% | Barclays | Carter Gould | $31 → $12 | Maintains | Overweight | Get Alert |
| 09/22/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 407.04% | B of A Securities | Greg Harrison | $41 → $27 | Maintains | Buy | Get Alert |
| 09/22/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 238.03% | Guggenheim | Vamil Divan | $25 → $18 | Maintains | Buy | Get Alert |
| 09/22/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 162.91% | Evercore ISI Group | Liisa Bayko | $30 → $14 | Maintains | Outperform | Get Alert |
| 09/22/2023 | TVTX | Buy Now | Travere Therapeutics | $5.33 | 238.03% | HC Wainwright & Co. | Ed Arce | $32 → $18 | Maintains | Buy | Get Alert |
FAQ
What is the target price for Travere Therapeutics (TVTX)?
The latest price target for Travere Therapeutics (NASDAQ: TVTX) was reported by HC Wainwright & Co. on April 24, 2024. The analyst firm set a price target for $19.00 expecting TVTX to rise to within 12 months (a possible 256.81% upside). 36 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for Travere Therapeutics (TVTX)?
The latest analyst rating for Travere Therapeutics (NASDAQ: TVTX) was provided by HC Wainwright & Co., and Travere Therapeutics maintained their buy rating.
When was the last upgrade for Travere Therapeutics (TVTX)?
The last upgrade for Travere Therapeutics Inc happened on December 5, 2023 when Citigroup raised their price target to $10. Citigroup previously had a neutral for Travere Therapeutics Inc.
When was the last downgrade for Travere Therapeutics (TVTX)?
The last downgrade for Travere Therapeutics Inc happened on March 27, 2024 when Guggenheim changed their price target from N/A to N/A for Travere Therapeutics Inc.
When is the next analyst rating going to be posted or updated for Travere Therapeutics (TVTX)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Travere Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Travere Therapeutics was filed on April 24, 2024 so you should expect the next rating to be made available sometime around April 24, 2025.
Is the Analyst Rating Travere Therapeutics (TVTX) correct?
While ratings are subjective and will change, the latest Travere Therapeutics (TVTX) rating was a maintained with a price target of $17.00 to $19.00. The current price Travere Therapeutics (TVTX) is trading at is $5.33, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.